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ROS signalingCellular oxidative stress results from the increased generation of reactive oxygen species and/or the dysfunction
of the antioxidant systems. Most intracellular reactive oxygen species derive from superoxide radical although
the majority of the biological effects of reactive oxygen species are mediated by hydrogen peroxide. In this con-
tributionwe overview themajor cellular sites of reactive oxygen species production,with special emphasis in the
mitochondrial pathways. Reactive oxygen species regulate signaling pathways involved in promoting survival
and cell death, proliferation, metabolic regulation, the activation of the antioxidant response, the control of
iron metabolism and Ca2+ signaling. The reversible oxidation of cysteines in transducers of reactive oxygen
species is the primary mechanism of regulation of the activity of these proteins. Next, we present the
mitochondrialH+-ATP synthase as a core hub in energy and cell death regulation, deﬁning both the rate of energy
metabolism and the reactive oxygen species-mediated cell death in response to chemotherapy. Twomainmech-
anisms that affect the expression and activity of the H+-ATP synthase down-regulate oxidative phosphorylation
in prevalent human carcinomas. In this context, we emphasize the prominent role played by the ATPase Inhibi-
tory Factor 1 in human carcinogenesis as an inhibitor of the H+-ATP synthase activity and a mediator of cell sur-
vival. The ATPase Inhibitory Factor 1 promotes metabolic rewiring to an enhanced aerobic glycolysis and the
subsequent production of mitochondrial reactive oxygen species. The generated reactive oxygen species are
able to reprogram the nucleus to support tumor development by arresting cell death. Overall, we discuss the
cross-talk between reactive oxygen species signaling and mitochondrial function that is crucial in determining
the cellular fate. This article is part of a Special Issue entitled: 18th European Bioenergetic Conference.
© 2014 Elsevier B.V. All rights reserved.kt murine thymoma viral onco-
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Oxidative stress is a phenotypic trait of many tumors. Main causes of
this phenotype are the increased generation of reactive oxygen species
(ROS) and the dysfunction of the antioxidant systems in cancer cells.
ROS generation and scavenging are tightly connected to the metabolic
state of the cell and especially to the activity of mitochondria. Nowa-
days, it is accepted that the roles played by cellular ROS are highly de-
pendent on the level at which they are being produced. In this regard,
it has been reported that high levels of ROS lead to increased cell
death inhibiting tumorigenesis and metastasis [1], whereas low levels
of ROS have an effect in promoting tumorigenesis by activating the
signaling pathways that regulate proliferation, angiogenesis andmetas-
tasis [2,3], stressing the relevance of ROS as important signaling mole-
cules that regulate cell fate. In this review we will brieﬂy summarize:
(i) the sites of production, mechanism of action and signaling pathways
that are activated by ROS and (ii) the role of the mitochondrial H+-ATP
synthase in ROS-signaling cell death or cell survival paying, in the latter
case, special attention to the newphysiological function unveiled for the
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phenotype in some prevalent carcinomas.
2. ROS dynamics and signaling
2.1. Major cellular sites of ROS production
Most intracellular ROS are derived from the superoxide radical (O2−),
which is the product of the one electron reduction of O2 (Fig. 1). Superox-
ide is then converted to hydrogen peroxide (H2O2) by superoxide
dismutases (SOD1, SOD2and SOD3) (Fig. 1). The enzymesperoxiredoxins
(PRXs), glutathione peroxidases (GPXs) and catalase are responsible for
removing cellular H2O2 (Fig. 1), a process that is tightly regulated [4].
H2O2 can also react with iron to generate hydroxyl radicals (•OH)
that are main drivers of the modiﬁcations in proteins, lipids and DNA
that result in oxidative stress (Fig. 1).
Several enzymes produce superoxide radical in the cell. Among
them, NADPH oxidase is the best described enzymatic source of super-
oxide that uses NADPH as an electron donor (Fig. 1) [5,6]. NADPH
oxidases include the Nox family members (Nox1–5) and the Dual oxi-
dase enzymes (Duox1–2) that are expressed in numerous tissues
[6–8]. These enzymes play important roles in cell signaling, regulation
of gene expression, cell death, differentiation and growth [9]. Nox en-
zymes have developed different regulatory mechanisms depending on
their function [6,8,10–12]. ROS produced by Nox proteins can act both
intra- and extra-cellularly. These enzymes generate superoxide at the
plasma membrane, in endosomes and in the endoplasmic reticulum
[13,14]. ROS produced by Nox2 have amain physiological role in the re-
spiratory burst that occurs in phagocytes. Nox1 in the colon and Duox1
and 2 in the lung also play important roles in host defense [15]. Howev-
er, ROS derived fromNox also participate in signaling as they can specif-
ically and reversibly alter the activity, localization and half-life of
proteins in response to various stimuli [9]. The phosphoinositide-3-
kinase (PI3K) [16] and nuclear factor kappa-light-chain-enhancer of
activated cell (NFkB) [13] pathways are two important signaling routes
in which NADPH oxidases are involved. Fibroblasts over-expressing
Nox1 displayed increased levels of superoxide and exhibited a trans-
formed phenotype [17]. Moreover, it has been described that Nox1NADPH oxidases
O2
SODs
O2-
Mitochondria
Fig. 1. Themetabolism of oxygen. Superoxide ismainly produced byNADPHoxidases and by the
superoxide dismutases (SODs). H2O2 is converted to water (H2O) by glutathione peroxidases (
because it can promote posttranslational modiﬁcations in proteins by thiol oxidation. The rea
lipid, protein and DNA damage, promoting oxidative stress.signals angiogenic and tumorigenic effects through hydrogen peroxide
[18]. Excess ROS produced by Nox5 have also been related to cancer
[19,20].
A substantial portion of cellular ROS is generated in mitochondria.
There are eight sites in mitochondria that have the ability to produce
ROS [21]. The mitochondrial electron transport chain (ETC) is the
major site of non-enzymatic formation of superoxide radical (Fig. 2).
The ETC is composed of four multiprotein complexes (I–IV) located
in the inner mitochondrial membrane. Complexes I, II and III have the
ability to produce superoxide as a result of the ﬂux of electrons through
the ETC. Complexes I, II and III produce ROS within the mitochondrial
matrix whereas complex III also generates ROS and releases it into the
intermembrane space (Fig. 2) [22]. Importantly, ROS generated in the
intermembrane space are supposed to access the cytosol in a faster
way which may confer them signaling advantages [3,23]. ROS are re-
leased to the cytosol through voltage-dependent channels that are con-
stituents of the permeability transition pore (PTP) and by the inner
membrane anion channel (IMAC) [24,25]. The transition of ROS from
mitochondria to the cytosol is crucial in the regulation of programmed
cell death geared by mitochondria [25,26].
Other important sources of mitochondrial ROS (mROS) are p66Shc
and monoamine oxidase (MAO) (Fig. 2). The protein p66Shc plays key
roles in the oxidative stress response by inducing apoptosis under
stressful conditions (Fig. 2) [27]. p66Shc acts as a redox protein due to
its capability to interact and oxidize cytochrome c (Fig. 2) [28]. MAO is
a ﬂavoenzyme bound to the outer mitochondrial membrane that cata-
lyzes the oxidative deamination of neurotransmitters andmonoamines.
MAO represents a signiﬁcant source of ROS production in brain mito-
chondria where it has been shown to generate ROS in a much higher
amount than the respiratory chain [29]. In fact, MAO is involved inmul-
tiple neuropathologies andmyocardial diseases and its inhibition is like-
ly to provide a promising target for the relief of the oxidative stress that
is associated with these pathologies [30].
The overproduction of ROS in response to metabolic stress triggered
by hypoxia or chemotherapy promotes an oxidative stress that has been
invariably linked to multiple pathologies including neurodegenerative
diseases, diabetes, cancer and premature aging [3]. Nowadays, it is
indubitable that mROS are important signaling intermediates in theCELLULAR
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Fig. 2. Overview of mitochondrial ROS production. The scheme shows the relevant sites of ROS production by mitochondria. The transfer of electrons obtained by the oxidation of NADH
and FADH2 to molecular oxygen by respiratory complexes in the inner mitochondrial membrane is depicted by continuous red lines. The formation of the proton gradient generated by
respiration and its utilization for the synthesis of ATP by theH+-ATP synthase in oxidative phosphorylation is indicated. Complexes I, II and III produce superoxide (discontinuous red lines,
ROS) and release it in the matrix. Complex III also releases ROS into the intermembrane space. The activity of the H+-ATP synthase also modulates the levels of ROS produced by mito-
chondria. ROS are also generated by the redox protein p66Shc which interacts with TOM–TIM protein import complexes and with cytochrome c (cyt c). MAO, which is located in the
outer mitochondrial membrane, represents an additional source of ROS in mitochondria.
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processes for maintenance of homeostasis under different conditions
and for adaptation to stress [3]. In fact, mROS can balance between sur-
vival and cell death in a process that is highly dependent on the levels at
which they are being produced [31]. For instance, themitochondrial re-
lease of H2O2 in hypoxia activates the transcription factor hypoxia in-
ducible factor 1 (HIF1α), which is required for metabolic adaptation
under low oxygen tension [32,33]. In addition, the mitochondrial re-
lease of H2O2 has been reported to activate key signaling proteins such
as c-Jun N-terminal kinase 1 (JNK1), p53 and NFkB [34–36]. Numerous
reports highlighting the importance of mROS-dependent signaling in a
variety of systems and processes have emerged in the literature of the
last decade [3,31,37–39].
It is well established that mROS production is highly dependent on
the protonmotive force as has been shown by titration of themitochon-
drialmembrane potential (Δψm)with uncouplers [40–42]. Perhaps, the
best characterized site of ROS production in mitochondria is at complex
III of the ETC (Fig. 2) [43]. The production of superoxide during forward
electron transfer at complex III is low but signiﬁcantly increases by re-
verse electron ﬂow under conditions of hypoxia [44] or cellular toxicity
[40,42] from substrates that feed electrons to complex II. The fact that
mitochondria produce more ROS under low oxygen levels is intriguing
because it seems to contradict the dependence of mROS formation on
the availability of oxygen that was observed in isolated mitochondria
[43,45]. It is likely that mROS generated in cells in response to hypoxia
depend on additional factors of the hypoxic cellular environment by
mechanisms that remain to be elucidated (see [43] for details). In gen-
eral, cellular conditions that slow-down the rate of electron transfer to
molecular oxygen in the respiratory chain (Fig. 2) at high values of
Δψm favor the generation of superoxide radical in mitochondria. Onesuch situation is provided by inhibition of the back-ﬂow of H+ through
the H+-ATP synthase (Fig. 2) that is mediated by the over-expression of
IF1 in human carcinomas [38,46–48] (see following section). In this sit-
uation, Δψm provides a link between energy metabolism, ROS produc-
tion and cell fate [47].
2.2. Cysteine oxidations regulate the activity of ROS transducers
The regulation of signaling pathways by ROS is exerted by their abil-
ity to promote reversible posttranslational modiﬁcations of proteins
[42,49,50]. Hydrogen peroxide is more stable than superoxide radical
and is also capable of crossing biological membranes so the protein
modiﬁcations mediated by ROS are predominantly H2O2-dependent.
However, superoxide itself has been shown to be involved in aging re-
lated processes [51]. H2O2 can reversibly oxidize thiol groups (\SH)
of redox-reactive cysteine (Cys) residues on proteins to form disulﬁde
bonds (\S\S\) or sulfenic acid (\SOH), the latter can be further oxi-
dize to sulﬁnic (\SO2H) and sulfonic (\SO3H) acids (Fig. 3) [31,52].
Sulphenic acid (\SOH) can react with glutathione (GSH) to become
glutathionylated (\SSG) (Fig. 3). These oxidative modiﬁcations result
in changes in the structure of the targeted proteins thereby affecting
its activity in the signaling pathways in which they are involved. In ad-
dition, the generation of intermolecular disulﬁde bonds can promote
the homo- and/or heterodimerization of proteins that lead to the activa-
tion or repression of the signal transducers. Thiol groups can also react
with reactive nitrogen species (RNS) forming S-nitrosothiol groups
(\SNO) (Fig. 3). With the exception of sulfonic and sulﬁnic acids that
are essentially irreversible reactions the modiﬁcation of cysteines is
reversible by the action of the reducing systems of the cell such as glu-
tathione, thioredoxin and peroxiredoxin (Fig. 3) that are critical
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Fig. 3. Regulation of protein activity by ROS. Proteins are regulated by ROS through the oxidation of thiol groups (\SH) of redox-reactive cysteine residues. Oxidation of these residues by
ROS can form reactive sulfenic acid (\SOH) that can undergo further oxidation to sulfonic (\SO3H) acid or form disulﬁde bonds with nearby cysteines (\SS\). These modiﬁcations lead
to the inactivation of the proteins. Disulﬁde bonds can be reduced by thioredoxin (TRX) reductase that recovers the activity of the protein. Sulphenic acid (\SOH) can also react with
glutathione (GSH) becoming glutathionylated (\SSG). Protein activity can be recovered by the action of glutaredoxin (GRX) that recognizes glutathionylated substrates and utilizes
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inactivation.
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such as phosphotyrosine protein phosphatase (PTP1b), phosphatase
and tensin homolog deleted on chromosome ten (PTEN) and MAPK
phosphatase are known examples of proteins involved in signaling
pathways inactivated by H2O2 oxidation of cysteines [56,57]. Superox-
ide also reacts with nitric oxide (NO), forming highly reactive and po-
tentially damaging peroxynitrite (OONO\) [58]. The formation of
peroxynitrite from O2− can lead to reversible glutathionylation of pro-
teins on reactive cysteines, as has been reported for theNa+–K+ATPase
[59]. The inactivation of aconitase by reaction of superoxide with (FeS)4
clusters provides an example of the inhibition of the activity of a meta-
bolic enzyme mediated by the interaction of O2− and iron [60,61].
2.3. Overview of signaling pathways regulated by ROS
Low or transient ROS levels can activate kinases and/or inhibit phos-
phatases involved in awide variety of cell signaling processes by oxidiz-
ing critical cysteine residues of the proteins (Fig. 4) [62,63]. Proteinases
and matrix metalloproteins have also been described as ROS targets
[64]. Thioredoxin that catalyzes the reversible reduction of disulﬁdes
to a dithiol in ROS targeted proteins (Fig. 3) interacts in its reduced
state with apoptosis signal-regulated kinase 1 (ASK1) that is activated
under oxidative stress (Fig. 4) [65]. Thioredoxin–ASK1 interaction
blocks oligomerization of ASK1 and its subsequent activation [66,67].
When thioredoxin is oxidized by ROS, it disassociates from ASK1
allowing protein oligomerization and subsequent activation through
auto-phosphorylation [68]. This kinase mediates apoptosis by regulat-
ing the JNK and p38MAPK pathways [69]. The regulation of differentia-
tion [70] and immune signaling [71]mediated by ASK1 through the p38
MAPK pathway are other important biological effects triggered by ROS.
Importantly, thioredoxin is also involved in the regulation of AMPKactivity by preventing the oxidation of cysteine residues in the α sub-
unit of the metabolic stress kinase [72]. This elegant study links oxida-
tive stress and metabolism demonstrating that a reducing enzyme is a
critical cofactor controlling the activation of AMPK, a key regulator of
metabolism and cell survival in situations of energy stress [72] (Fig. 4).
The best-characterized example of ROS-mediated inactivation of
phosphatases by the oxidation of the active site cysteine residue of
the enzyme is that of protein tyrosine phosphatase 1b (PTP1b). The
inactivation of this enzyme results in the promotion of MAPK and
growth factor signaling pathways initiated from different stimulus
(Fig. 4) [62,73–76]. Additionally, ROS can inactivate the dual-speciﬁc
phosphatase 3 (DUSP3) that is another protein tyrosine phosphatase
involved in the dephosphorylation of ERK1/2 causing the sustained acti-
vation of the ERK1/2 signaling pathway [77] that plays an essential role in
cell proliferation, differentiation, invasion, and apoptosis [78–80].
The PI3Kpathwaywhich is important for cellular growth, survival and
proliferation (Fig. 4) [81] can be affected by the redox state of the cell
through different mechanisms [82]. For example, Akt that is a main pro-
tein kinase downstream in the pathway has been shown to be activated
byH2O2 [83]. The target of ROS in the PI3Kpathway is the tumor suppres-
sor PTEN, a phospholipid phosphatase that converts PIP3 back to PIP2
thus acting as a negative regulator of the pathway [82,84]. PTEN is
inhibited by hydrogen peroxide through disulﬁde bond formation be-
tween the active site cysteine (Cys124) and a vicinal cysteine residue
[85–87]. Through PTEN, the PI3K pathway is subject to reversible redox
regulation by ROS generated by growth factor stimulation [88]. PTEN ox-
idation is reversed by cytoplasmic peroxiredoxin II that eliminates the
H2O2 generated in response to growth factors [85]. Mitochondrial-
generated ROS can also inhibit PTEN affecting the angiogenesis process
[89]. Protein phosphatase 2A (PP2A) which is involved in the dephos-
phorylation of Akt [90] and the inactivation of the PI3K/Akt pathway
Fig. 4. Signaling pathways regulated by ROS. ROS regulate several signaling pathways with key roles in cellular processes by affecting the activity of critical molecules. ROS can mediate
survival, proliferation, metabolism and cell death by regulating the activity of proteins involved in MAPK pathways such as, ASK1, PTP1b, and DUSP3. Proteins participating in the PI3K
pathway such as AKT, PTEN, PP2A and ATM are also direct targets of ROS. HIF1α, p66Shc and AMPK are also regulated by ROS. ROSmodulate the antioxidant response through the action
of REF1 and NRF2. The iron regulatory proteins IRP1 and IRP2 that are involved in iron homeostasis and InsP3R, RyR and SERCA that participate in the regulation of Ca2+ signaling are also
targeted by ROS.
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tant phosphatases the AKT signaling pathway is deregulated promoting
uncontrolled cellular proliferation and enhanced survival and growth.
Ataxia-telangiectasia mutated (ATM) protein (Fig. 4) is a PI3K-like
serine/threonine protein kinase that is activated under stressful condi-
tions and phosphorylates various proteins involved in cellular prolifera-
tion, death, survival and DNA repair [92,93]. ATM is preferentially
activated by DNA double strand breaks and also acts as a sensor of
oxidative stress [94]. ATM protein is also regulated by a redox sensitive
mechanism via the formation of active ATM dimers through inter-
molecular disulﬁde bond formation (Fig. 3) [95].
The hypoxia inducible transcription factor HIF1α is also a target of
ROS (Fig. 4) [23]. HIF1α is responsible for the coordination of the cellu-
lar responses to decrease oxygen availability [96,97]. During normoxia
prolyl hydroxylation of HIF1α promotes its association with the von
Hippel–Lindau (VHL) tumor suppressor that targets the protein for
ubiquitination anddegradation.However, duringhypoxia thehydroxyl-
ation of proline inHIF1α is inhibited due to the inactivation of prolyl hy-
droxylases. mROS are involved in the stabilization of HIF1α to promote
the transcriptional activity of the protein [32,98–101]. The stabilization
of HIF1α under low oxygen conditions requires the generation of ROS in
complex III of the ETC [102]. In other words, the mitochondrial respira-
tory chain acts as an O2 sensor that activates a signaling cascade to sta-
bilize HIF1α through the production of ROS. First evidences illustrating
that mROS are involved in the regulation of HIF1α aroused from studies
in cells depleted of mitochondrial DNA (ρo cells) that failed to stabilize
HIF1α under hypoxia [32]. HIF1α stabilization is blunted by treating
the cells with mitochondrial antioxidants emphasizing that mitochon-
dria are the source of ROS under hypoxic conditions [32,33]. Moreover,
inhibitors of the mitochondrial electron transport chain that block
HIF1α activation in hypoxia have also been described [103]. ThemROS mediated regulation of HIF1α is implicated in regulating tumor-
igenesis by controlling genes involved inmetabolism, angiogenesis, and
metastasis [97,104].
As discussed previously mROS produced in p66Shc play relevant
roles in the activation of the apoptotic pathway and in the regulation
of life span [27]. The production of mROS by this protein leads to mito-
chondrial damage and apoptosis under oxidative or genotoxic stress
conditions [105]. The mechanisms that mediate mitochondrial translo-
cation of p66Shc and its proapoptotic activity seem to be controlled
by protein phosphorylation [106], although it has also been suggested
that ROS production and the initiation of apoptosis by p66Shc are also
redox sensitive by formation of two disulﬁde bonds in the protein
(Fig. 4) [107]. The interaction observed between p66Shc with the
TOM–TIM protein import complexes [105,108] and with cytochrome c
[28] is also a mechanism involved in the proapoptotic function of the
protein (Fig. 2).
An important point in the cellular response to increased levels of
ROS is the redox regulation of transcription factors that activate the an-
tioxidant defense system (Fig. 4). The transcription factor redox factor-1
(Ref-1) is a multifunctional protein that translocates to the nucleus
upon exposure to genotoxic agents and H2O2 and initiates a protective
response of the cell from DNA and oxidative damage [109,110]. Ref-1
regulates the transcriptional activity of several key transcription factors
involved in cellular defense such as activator protein 1 (AP-1), p53,
NFkB and HIF1α by its redox sensitive cysteine residues [111–113].
The antioxidant genes glutathione S-transferase (GST) [114], NADPH
quinone oxidoreductase-1 (NQO1) [115] and heme oxygenase-1
(HO1) [116,117] are regulated by an enhancer termed the antioxidant
responsive element (ARE) [118]. H2O2 activates transcription of these
genes via the ARE element and involves a complex set of redox regulat-
ed proteins [119]. The primary transcription factor involved in ARE
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[120] (Fig. 4) that is translocated into the nucleus under oxidative stress
[121]. In the nucleus Nrf2 dimerizes with the small Maf proteins and
binds the ARE to activate ARE-dependent transcription of target genes
in ROS homeostasis [118,122]. Interestingly, the transcriptional activity
of Nrf2 is also regulated by Ref-1 [123] indicating the collaboration of
these proteins in the detoxiﬁcation of the cell under oxidative stress.
Extensive literature has related ROS and Ca2+ signaling and their ef-
fects on apoptosis, aging and cardiovascular diseases [124] (Fig. 4). ROS
can modify the properties and activities of some of Ca2+ channels and
transporters [125,126]. In fact, some of the proteins involved in Ca2+
signaling such as the InsP3 receptor (InsP3R) [127], the ryanodine re-
ceptor (RyR) channels [128] and the sarco/endo-plasmic reticulum
Ca2+-ATPase (SERCA) [129] have been shown to be sensitive to ROS.
In addition, ROS signaling is also important for the maintenance of
iron homeostasis (Fig. 4). Iron is an essential element that plays crucial
roles in cell proliferation and metabolism as it represents a functional
constituent of various enzymes. Excessive levels of free iron can gener-
ate ROS via the Fenton reaction [130,131] promoting deleterious oxida-
tive stress to the cells (Fig. 1). Iron regulatory proteins-1 and -2 (IRP1
and IRP2) regulate the expression of many genes involved in iron trans-
port and storage at the posttranscriptional level by interacting with
iron-responsive elements (IRE) in the 5′- or 3′-untranslated region
(UTR) of the mRNAs. IRP1 and IRP2 have redox sensitive target sites
that are subjected to redox regulation by H2O2 and nitric oxide
[132–135]. Taken together, the IRE–IRP regulatory system is also regu-
lated by ROS to elicit a defensemechanismagainst iron-catalyzed oxida-
tive stress.
3. Old and new functions of the H+-ATP synthase
3.1. The H+-ATP synthase, a core hub in energy and cell death regulation
The oxidation of glucose in the cytoplasm and the subsequent oxida-
tion of pyruvate in mitochondria provide the energy, reducing power
and carbon skeletons required for the maintenance of cellular homeo-
stasis and proliferation [47,136]. Normoxic cells oxidize most of the py-
ruvate to CO2 in mitochondria and the electrons collected onto NADH
and FADH2 are transferred to the complexes of the respiratory chain
to generate the proton electrochemical gradient that is used for the syn-
thesis of ATP in oxidative phosphorylation (OXPHOS) (Fig. 2). ATP is
synthesized by themitochondrial H+-ATP synthase, a reversible engine
of the inner mitochondrial membrane that provides most of the
ATP that is required to maintain cellular activities in normal aerobic dif-
ferentiated cells [47]. Themammalian H+-ATP synthase consists of two
main domains: a membrane-bound hydrophobic FO portion, which
contains the proton channel, and the soluble catalytic F1 portion
that encloses the adenine nucleotide binding sites at theα/β subunit in-
terface [137,138]. Both regions are linked together by a central and a pe-
ripheral stalk. In normal aerobic cells under phosphorylating conditions,
the re-entrance of protons into the mitochondrial matrix (Fig. 2) trig-
gers the rotation of the c-ring in FO and of the attached central stalk to
induce the conformational changes in the β-F1-ATPase subunit that
drive the synthesis of ATP (Fig. 2).
The cellular availability of ATP, NADH and somemetabolic interme-
diates coordinates at short-term the ﬂux of glucose consumption by
regulating the activity of key enzymes of the glycolytic pathway andmi-
tochondrial dehydrogenases, to limit the production of biological ener-
gy as it is being demanded [47]. In other words, the efﬁcient production
of biological energy by OXPHOS determines the rate of glucose con-
sumption, which is nowadays formulation of the Pasteur Effect [139].
When the cells have a limited supply of oxygen or have a genetic or epi-
genetic impairment that restrains OXPHOS, glycolysis is enhanced [47,
140].When short-term regulation of enzymeactivities of energymetab-
olism is not enough to cope with the energetic demand cells onset the
gene expression programs required for adaptation. Examples that arerelevant in this regard are the induction of glycolysis during adaptation
to hypoxia [141], the rewiring of metabolism in cancer [142] and in de-
differentiation of somatic cells [143], the onset of the bioenergetic func-
tion of mitochondria during adaptation of mammals to the aerobic
extrauterine environment [144,145] and the metabolic reprogramming
that accompanies stem cell differentiation [146,147].
3.2. The H+-ATP synthase in signaling cell death
Down-regulation of oxidative phosphorylation (OXPHOS) and the
concurrent activation of aerobic glycolysis are hallmarks of proliferating
cancer cells [140,148].Whereas the increase of glycolysis in themajority
of carcinomas is nowadays out of question, the role of OXPHOS modiﬁ-
cations in tumor development andprogression is still debated [47]. Nev-
ertheless, it has been shown that a dysfunctional OXPHOS promotes
cellular proliferation and invasion [47,149] whereas an increase in oxi-
dative metabolism halts cellular proliferation and tumor progression
[47,140,150,151]. In this regard, the activity of OXPHOS has been dem-
onstrated to be speciﬁcally required for the execution of cell death
[47,152–154]. In particular, molecular components that participate in
OXPHOS, such as cyt c, AIF and subunits of the H+-ATP synthase are
needed for the execution of cell death [40,155–158]. Hence, bioenerget-
ics and cell death are two master tasks of mitochondria that are molec-
ularly and functionally integrated [47].
The impairment of mitochondrial energy production by metabolic
stress and/or in response to chemotherapy leads to increased ROS
generation through respiratory chain electron leakage. ROS can signal
mitochondrial geared cell-death pathways or activate transcription pro-
grams aimed at cell survival, two opposite cellular fates that largely de-
pend on the intensity of theROS signal [1,31]. The induction of cell death
by different stressful conditions promotes Δψm collapse that is preced-
ed by transient mitochondrial hyperpolarization [40,156,159] and the
subsequent production of mROS which is highly dependent on Δψm
[40,42,160]. It has been suggested that mROS produced in response to
cell death stimulation occurs by reverse electron ﬂow from complex
II-linked respiratory substrates into complex I of the ETC (Fig. 2)
because its production can be inhibited with rotenone [40,42,161].
Consistent with a role for mROS in the execution of cell death [1,162],
extensive protein carbonylation of cellular proteins as well as covalent
modiﬁcations inmitochondrial proteins have been reported in response
to staurosporine treatment [40]. The generation of mROS preceded the
release of cyt c, the activation of caspase 3 and cell death [40]. Upon in-
hibition of mitochondrial respiration with staurosporine [163] it is sug-
gested that the hydrolysis of glycolytic ATP by reverse functioning of the
H+-ATP synthasemaintainsΔψm [40,164–166]. In this situation, the in-
hibition of the activity of the H+-ATP synthase with oligomycin blunted
mitochondrial hyperpolarization and ROS production, prevented the
oxidation and modiﬁcation of mitochondrial proteins, and delayed the
release of cyt c and the execution of cell death [40,164].
In contrast to these ﬁndings, 1,4-benzodiazepine-derivative Bz-423
signals apoptosis by the induction of ROS production from the mito-
chondrial respiratory chain as a result of the inhibition of the H+-ATP
synthase [167]. The antagonistic effects on apoptosis of oligomycin
and Bz-423 seem to be dependent on the different mechanism by
which these compounds inhibit the enzyme [167]. Similarly, the drug
3,3′-diindolylmethane also promotes ROS-mediated cell death by
inhibiting the H+-ATP synthase [168]. In any case, these ﬁndings
support a role for the activity of the H+-ATP synthase in controlling
the extent of oxidative damage to mitochondrial constituents that will
effectively swamp the cells into death [40]. Consistently, the cell death
response to different chemotherapeutic agents varies largely depending
upon the relative activity of the pathways that sustain energy metabo-
lism (Fig. 5) [40,169]. In fact, highly glycolytic cells with negligible con-
tribution of OXPHOS for ATP provision have a cell-death resistant
phenotype because mROS signaling after chemotherapeutic targeting
is blunted (Fig. 5) [40,169]. Overall, the down-regulation of the H+-
Chemotherapy
Cancer Cell
OXPHOS GLYCOLYSIS
SORoNSOR
Cell death resistant 
phenotype
Cell death (apoptosis)
Fig. 5. Energymetabolism determines the cell-death pathway of cancer cells. Susceptibility of cancer cells to death stimulus is highly dependent on their metabolic phenotype. The rapid
dismantling and fragmentation of themitochondrial tubular network into smallmitochondria (green) occur as aﬁrst response to a death stimulus to chemotherapeutic agents. Tumor cells
with a signiﬁcant activity of oxidative phosphorylation (OXPHOS) will produce high levels of ROS contributing to the oxidation ofmitochondrial proteins (red dots) and the release of the
mitochondrial arsenal involved in the execution of cell death (fragmented nucleus in yellow). Cells with a diminished activity of OXPHOS and thus an increased activity of the glycolytic
pathway will not generate ROS under conventional chemotherapy which results in a resistant cell death phenotype.
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adapted by cancer cells to avoid reactive oxygen species-mediated cell
death.
Interestingly, it has been shown that the activity of the H+-ATP
synthase per se is inhibited by ROS [170,171]. The impact of ROS on
the activity of the complex is also observed in chloroplasts where the
γ subunit seems to be a main target for ROS oxidation [172]. These
ﬁndings further emphasize the tightly regulated connections that exist
between the H+-ATP synthase, energy production, ROS generation
and cell death.
The point of no return in cell death is the permeabilization of the
inner mitochondrial membrane to low molecular weight solutes, the
so-called PTP opening [173–175]. Although the molecular composition
of the PTP remains unknown recentﬁndings support that a critical com-
ponent of the high-conductance channel is subunit c of the H+-ATP syn-
thase [176]. Moreover, it has been shown that dimers of the H+-ATP
synthase form a channel with electrophysiological properties identical
to those of the PTP [177]. Non-speciﬁc ROS-mediated modiﬁcations of
mitochondrial constituents could represent a critical point of regulation
of themitochondria-geared cell death pathway. Protein oxidation could
deﬁne the threshold value of irreversible damage of the mitochondria
and the set-point for the release of the mitochondrial arsenal that
controls cell death (Fig. 5) [40]. Indeed, oxidative stress promotes cell
death by increasing the susceptibility of the opening of the PTP [178].
PTP opening is linked to oxidative stress since it has been shown to be
dependent on the NADPH redox state [179,180] and promoted by
thiol oxidation [181,182]. Consistently, it has been reported that PTP
opening can be stimulated by the addition of exogenous sources of
ROS and prevented by antioxidants in pro-apoptotic conditions [180].
Interestingly, PTP opening also increasesmitochondrial ROS production
illustrating a retro-ampliﬁcation cascade when the decision to execute
cell-death has been taken [183].
Consistent with the tumor suppressor function of mitochondrial ac-
tivity there is a large body of data supporting that OXPHOS, both underbasal conditions or in response to chemotherapeutic agents abolishes
tumorigenicity (see [47] for updated review). A likely mechanism that
explains the preferential death of cancer cells when forced to oxidize
mitochondrial substrates is the overproduction of superoxide radical
as a result of the stimulation of mitochondrial metabolism [40,47,184].
Both genetic [185] and pharmacological [186] studies have shown that
the PGC1α-mediated improvement of mitochondrial activity and
metabolism restrains cancer progression by increasing ROS-mediated
apoptosis in cancer cells [185].
A diverse set of genetic, epigenetic and environmental mediated
mechanisms interfere with mitochondrial bioenergetics of the cancer
cell [47,187]. One such mechanism, which is observed in many preva-
lent human carcinomas, is the down-regulation of the expression
of the catalytic subunit of the mitochondrial H+-ATP synthase (β-F1-
ATPase) relative to the enzyme of glycolysis glyceraldehyde-3-
phosphate dehydrogenase [140,188]. This ﬁnding has been conﬁrmed
and extended to other carcinomas (see [140] for other studies), provid-
ing a “bioenergetic signature” of cancer [140,188] of clinical applicabili-
ty. Indeed, as assessed in large cohorts of colon [188–190], lung [191,
192], breast [193] and ovarian carcinomas [194] and in cells of acute
myeloid leukemia patients [195] the altered bioenergetic signature of
the tumors predicts a worst overall and/or disease-free survival for the
patients. Down-regulation of the bioenergetic signature is also function-
ally linked to the resistance to chemotherapy in many different cancer
cells [47,196,197], in colon cancer patients [190] and in chronic [198]
and acute [195] leukemia patients. In general, the bioenergetic signature
represents a functional index ofmetabolic activity of the cells because it
correlates, both in vitro [199] and in vivo [192], with the rate of glucose
utilization. Overall, theseﬁndings emphasize that a diminished bioener-
getic activity of mitochondria in the cancer cell predisposes to cancer
onset and progression, highlighting the emerging role that the H+-
ATP synthase plays as a master regulator of cell death [40,156,177,200,
201]. Consistently, cancer progression requires the silencing of the bio-
energetic activity of mitochondria [199] not only by down-regulating
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over-expressing the natural physiological inhibitor of the enzyme, the
so-called ATPase Inhibitory Factor 1 (IF1) [38,46,47].3.3. The ATPase Inhibitory Factor 1 (IF1)
Inmitochondria, ATP hydrolysis by the H+-ATP synthase is inhibited
by the ATPase Inhibitory Factor 1 (IF1) that reversibly binds to the en-
zyme (Fig. 6) [202,203]. The natural inhibitor of the H+-ATP synthase
is a low molecular weight (~10 kDa) mitochondrial protein which
inhibited the soluble ATPase, but did not interfere with its coupling ac-
tivity [204]. IF1 is encoded in the nuclear ATPIF1 gene located on chro-
mosomes 1 and 4 in human and mouse, respectively. IF1 has been
described in mammals, birds, amphibious, nematodes, yeast and plants
and shows considerable sequence identity among various eukaryotes
[205]. It is absent in bacteria and chloroplasts. Three different isoforms
of the human protein are produced by alternative splicing. Isoform 1 is
the longest one, it codiﬁes for a protein of 106 amino acids (12.2 kDa;
pI = 10) which is, by far, the protein more abundantly expressed in
most human tissues [46,47]. Isoforms 2 and 3 codify for proteins of 71
(7.9 kDa; pI= 8.5) and 60 (6.6 kDa; pI= 9.3) amino acids, respectively.
The inhibitor protein has an N-terminal presequence of 25 residues for
targeting the protein into the mitochondrial matrix which is cleaved
off after import [206,207].
The interaction between IF1 and the H+-ATP synthase depends on
the pH of the mitochondrial matrix and is affected by changes in the
Δψm [202,207]. IF1 binds β, α and γ subunits of the H+-ATP synthase
due to its activation under low pH conditions blocking ATP hydrolysis
and preventing a useless waste of energy [207]. The substitution of his-
tidine 49 in the IF1 sequence by a lysine renders a mutant form of IF1
(H49K) that is as active as IF1 in the inhibition of the ATP hydrolase ac-
tivity but less sensitive to the regulation by pH [138,202,203,208,209].
The participation of E26 in the pH regulated inhibitory activity of bovine
IF1 has also been suggested [210]. Bovine IF1 has been shown to
have oligomeric states, tetramer and dimer, favored by pH values
above and below 6.7, respectively [202]. Dimerization and activation
of IF1 occur by formation of an antiparallel α-helical coiled-coil in its
C-terminal region which places the N-terminus (inhibitory regions) ofIF1 IF1
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Fig. 6. IF1 mediates the oncogenic phenotype by ROS signaling. The illustration shows a schem
and labeled. In tumor cells, the ATPase Inhibitory Factor 1 (IF1) (in red) is highly over-expressed
metabolic reprogramming towards an enhanced glycolytic phenotype. Inhibition of the H+-A
and the subsequent increase in superoxide radical production (ROS). ROS signaling will activat
hallmarks of cancer as they promote tumorigenesis and metastasis.the monomers at opposite ends of the dimer, allowing the dimeric IF1
to bind two domains of F1-ATPase simultaneously [202]. The structure
of the inhibited F1-ATPase complex with bound IF1 in the presence of
ATP has been solved and conﬁrms that the N-terminal region of the di-
meric inhibitor is bound to F1-ATPase [138]. The inhibitory 42L–58K
segment of IF1 has been shown to interact with α/β pair of subunits
of the F1-ATPase domain. It is suggested that this interaction inhibits
the conformational inter-conversions of the catalytic sites involved in
ATP hydrolysis and hence rotatory catalysis [138]. Hence, the mecha-
nism of inhibition of the ATPase by IF1 arises from the disruption of
the catalytic site.
The physiological function ascribed to IF1 in normal hypoxic cells is
to inhibit the hydrolase activity of the H+-ATP synthase [202,203,211,
212]. Until recently, the role of IF1 in preserving cellular ATP inmyocar-
dial ischemia [209,211] and in ischemic preconditioning [209] has been
themost extensively studied functions of IF1. However, the transforma-
tion of mitochondria from ATP producers into ATP consumers under
depolarizing conditions has been recently questioned [213]. Uponmito-
chondrial depolarization IF1 has been identiﬁed as an essential gene to
promote PARK2 recruitment onto mitochondria to establish the selec-
tive autophagic program of mitophagy [214]. More recent ﬁndings sup-
port a relevant role for IF1 in controlling the ferrochelatase activity of
mitochondria, and hence heme biosynthesis, in erythroid cells [215].
Surprisingly, a recently ill-deﬁned knockout IF1 mouse model has re-
vealed no alterations in phenotype [216]. The absence of IF1 is known
to occur in Luft's disease, amitochondrialmyopathy of the striatedmus-
cle [209,217,218]. The disorder is characterized by a hypermetabolic
state, mitochondria with densely packed cristae and a loosely coupled
OXPHOS [209,217,219], suggesting additional functional roles for IF1
in the regulation of the H+-ATP synthase of muscle mitochondria.
It has been shown that long rows of dimers of the H+-ATP synthase
promote the high local curvature of the inner membrane at
cristae ridges [220–223]. Interestingly, aging seems to melt down the
inner-membrane cristae ofmitochondria by age-dependent dissociation
of ATP synthase dimers [224]. It has been suggested that IF1 regulates
the oligomeric state of the H+-ATP synthase increasing the
density of cristae and the formation of dimeric ATP synthase complexes
[212,225–227]. However, this suggestion has been questioned
[228–230].ROS
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cells
Adifferential expression level of IF1 has been reported between differ-
entmouse [231] and human tissues [46,48]. Moreover, cardiomyocytes of
low heart rate species (human) have a higher expression level of IF1 than
cardiomyocytes of fast heart rate species (rat, mouse) [209,211], which
might explain the differential preservation of cellular ATP upon sublethal
ischemic episodes. Interestingly, normal colon, lung and breast tissue
have negligible expression of IF1 [38,46,48]. In contrast, mitochondria of
almost all lung, colon, breast and ovarian carcinomas analyzed in large co-
horts of cancerpatients showanoverwhelming increase in the expression
of IF1 [48]. We have demonstrated that the over-expression of IF1 results
in the inhibition of the ATP synthetic activity of the H+-ATP synthase and
the switch of the cells to an enhanced aerobic glycolysis [38,46]. On the
contrary, silencing of IF1 enhances the H+-ATP synthase activity and re-
duces aerobic glycolysis, strongly supporting a crucial role for IF1 inmedi-
ating the metabolic switch experienced by cancer cells [38,46]. Likewise,
IF1 is present in human mesenchymal stem cells (hMSCs) as well as in
stem cells of the prostate and in the Lieberkühn crypts of the colon
[147]. Consistentwith amaster role for IF1 in the regulation of energyme-
tabolism we have shown that the regulated degradation of IF1 triggers
metabolic rewiring from aerobic glycolysis to a predominant OXPHOS in
the differentiation process of hMSCs into osteocytes [147], once again
stressing the biological relevance of this protein in regulating energy me-
tabolism of proliferating cells.
3.5. The role of IF1 in ROS signaling cell survival
The IF1-mediated inhibition of the H+-ATP synthase results in mito-
chondrial hyperpolarization and the subsequent production of superox-
ide radical in colon [38] and other cancer [48] cells (Fig. 6). Therefore,
besides the role of IF1 in rewiring energy metabolism [46,232], the
over-expression of IF1 also triggers a retrograde ROS signal to the nucle-
us to establish the appropriate adaptive cellular program needed to
support tumor development [38,48]. IF1 mimics the inhibitory effect
of oligomycin in reprogramming energy metabolism and in inhibiting
apoptosis [40,156]. Remarkably, it has been demonstrated that the
ROS-mediated response in colon cancer cells in response to the over-
expression of IF1 signals to the nucleus an NF-κB-dependent adaptation
that includes enhanced proliferation, invasion and cell survival [38]. An
IF1 ROS-mediated resistance to cell death has also been demonstrated
in other cancer cells [48]. The ROS-signaling pathways (Fig. 4) activated
in response to IF1 over-expression that arrest cell death in many preva-
lent human cancer cells still remain to be investigated [48]. An alterna-
tive, not mutually exclusive mechanism of action of IF1 to prevent cell
death is that it might contribute to stabilize the oligomerization state
of the H+-ATP synthase to preserve mitochondrial cristae impeding in
this way the release of cyt c [233]. In this regard, IF1 has been suggested
to increase the density of mitochondrial cristae by the formation of
dimeric ATP synthase complexes [212]. In this situation, IF1 would
represent a negative regulator of PTP opening [177] contributing to
the evasion of cell death. Consistently, recent ﬁndings in a conditional
transgenic mouse expressing H49K (a gain-of-function mutant of
human IF1) in neurons that also inhibits the H+-ATP synthase support
a ROS-mediated metabolic and structural pathway to prevent neuronal
cell death in vivo after an excitotoxic insult [234]. Overall, theseﬁndings
strongly support that IF1 plays a master role in the regulation of energy
metabolism and in retrograde communication to the nucleus other fea-
tures of the oncogenic phenotype such as cell survival [47,187].
3.6. Regulation of IF1 activity and expression and other IF1 paradoxes
In silico analysis of the promoter region of the human ATPIF1 gene
reveals the existence of potential cis-acting responsive elements for
transcription factors involved in cancer. Data from high-throughputChiP-sequencing conﬁrmed the binding of several transcription factors
involved in the regulation of cell cycle (NF-YB, NF-YA, Ini1), prolifera-
tion (c-FOS, Sp1, c-MYC) inﬂammation and cell death (NFκB, TAF1) in
the proximal promoter region of the ATPIF1 gene. However, the regula-
tion of IF1 expression in human carcinomas is exerted at post-
transcriptional levels [48]. In fact, IF1 has a very short half-life (~2 h)
in colon cancer cells [48] being degraded by a mitochondrial protease
[147]. However, themitochondrial protease involved in IF1 degradation
has not been identiﬁed despite our recent attempts using a large siRNA
screen [147]. It has been suggested that the hypoxia regulated transcrip-
tion factor HIF1α participates in controlling IF1 expression (Fig. 4)
[235]. Moreover, it has been shown that the immediate early response
gene (IER3) binds the C-terminus of IF1 to render the protein prone to
proteolytic digestion inHeLa cells [236]. However, recentﬁndings in dif-
ferent cancer cell lines seem to exclude the participation of HIF1α [48]
and of IER3 [48] in controlling IF1 expression in colon, lung and breast
carcinomas.
Paradoxically, tissues with very high activity of OXPHOS (liver, mus-
cle, neurons) show a very high content of IF1 [38,46,48,234], which
would imply the partial IF1-mediated inhibition of theH+-ATP synthase
in these tissues, which is obviously not the case. As recently pointed out
[48], these ﬁndings suggest that besides the well characterized pH con-
trolled binding of IF1 to β-F1-ATPase [202], an additional mechanism
should regulate the biological activity of IF1 specially in tissues that nat-
urally over-express the protein. It has been described that IF1, in addi-
tion to binding subunits of the H+-ATP synthase, also binds other
membrane proteins of mitochondria in a pH and Δψm independent
manner [237]. Speciﬁcally, it has been shown that the binding to one
of these membrane proteins (~5–6 kDa) hampers the activity of IF1 as
an inhibitor of the ATPase [237]. Hence, it is conceivable that tissues
that normally over-express IF1 could also express a putative receptor
that might act as a negative regulator of IF1 in order to counterbalance
its inhibitory activity, contributing in this way to the ﬁne-tuning of
OXPHOS. Alternatively, tissue-speciﬁc post-translational modiﬁcations
of IF1 [238] could explain its activity on the H+-ATP synthase. The bio-
logical relevance of these modiﬁcations and the proteins and signals
involved are unknown but they are likely to be relevant to understand
IF1 expression and activity.
Interestingly, the study of IF1 expression in tumors of large cohorts
of breast and colon cancer patients supports that it represents a marker
of clinical outcome [48]. Surprisingly, colon and breast cancer patients
with high tumor expression of IF1 have a better prognosis in terms
of time of disease relapse [48] which suggests that cancer cells with a
low expression of IF1 should bemore likely tometastasize [48]. Themo-
lecular bases of this paradox are presently unknown.
4. Final remarks
We have outlined the main pathways that lead to superoxide pro-
duction in mitochondria, the primary mechanism by which ROSmodu-
late the activity of proteins involved in signaling pathways and their
biological consequences in the cell response. The mitochondrial H+-
ATP synthase is presented as a key transducer in controlling energyme-
tabolism, ROS-mediated cell death or the retrograde ROS response that
allows the acquisition of an enhanced proliferation and the resistance to
cell death, key features of the phenotype observed in carcinomas. ROS
signaling bymitochondria is important in cancer onset and progression
and it might represent the remnant mechanism that allowed the suc-
cessful symbiosis of the two organisms that gave rise to the aerobic eu-
karyotic cell. A master regulator of mitochondrial ROS production with
clear effects in promoting the malignant phenotype of cancer cells is
the ATPase Inhibitory Factor 1. Characterizing the regulation of its
expression and/or activity is a critical issue to understand the regulation
of OXPHOS in different mammalian tissues and of many of the hall-
marks of the cancer phenotype. The development of tissue speciﬁc
mouse models with regulated expression of IF1 will contribute to
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Overall, we can conclude that bioenergetics, ROS production and cell
death are master tasks of mitochondria that are molecularly and func-
tionally integrated. Unveiling the mechanisms that mediate these sig-
naling networks will bring up new opportunities for cancer therapies.Acknowledgements
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